News Release

Prescient Medicine Holdings is Now SOLVD Health

SOLVD Health’s mission is to prevent disease by making actionable health information accessible to everyone

CARLSBAD, Calif., December 1, 2020 – Prescient Medicine Holdings, Inc., a privately held company focused on developing insights-based health tools, today announced its rebrand to SOLVD Health. The new name and brand reflect the company’s mission to solve some of healthcare’s biggest challenges through preventative health solutions that combine genetics-based patient insights with cutting-edge technologies.

“As we drive toward commercialization of our two breakthrough tests for opioid use disorder and colon cancer, we believe the time is right to evolve our brand to reflect the current and future potential of our innovation platform,” said Keri Donaldson, M.D., Chief Executive Officer of SOLVD Health. “At SOLVD Health, our goal is to create much-needed predictive and actionable health insight tools and make them available to healthcare providers and their patients.”

SOLVD Health will focus on the development and commercialization of its innovative technologies, which utilize machine learning and custom algorithms. These technologies include two groundbreaking tests, which have both been granted Breakthrough Device designations by the U.S. Food and Drug Administration (FDA). One is a genetic test designed to identify people at increased risk for opioid use disorder (OUD) prior to taking oral prescription opioids. The other test analyzes an individual’s microbiome and is designed to detect colorectal cancer and precancerous adenomas.

“At SOLVD Health, we aim to prevent people from becoming patients,” said Dr. Donaldson. “By providing contextualized insights before symptoms occur – a model that we call Patient Intelligence – we can improve patients’ lives while also changing how we think about and conduct healthcare as a society.”

To learn more, visit the new SOLVD Health website at www.solvdhealth.com.

About SOLVD Health

SOLVD Health is a privately held company focused on preventing disease by making contextual health information accessible to everyone. Through the development of insights-based health tools, we are enabling individuals and their providers to make better decisions about their health and the health of their families. We accomplish this by translating complex biological signals into actionable patient data that can point the way to better health. To learn more about us, our solutions, and our career opportunities, visit us on LinkedIn or at www.solvdhealth.com.

Media Contact:
Valerie Melucci; pr@solvdhealth.com 

 

SOLVD Health Launches 5-Year Post-Approval Study on Real-World Impact for AvertD® Genetic Test

SOLVD Health Launches 5-Year Post-Approval Study on Real-World Impact for AvertD® Genetic Test

November 18, 2024 — SOLVD Health has launched a comprehensive post-approval study for AvertD®, the first U.S. Food and Drug Administration (FDA)-approved genetic test for assessing risk of developing opioid use disorder (OUD). This study aims to expand upon pivotal study findings and further demonstrate AvertD’s ability to enhance personalized data-driven decisions in real-world settings.

read more